Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Cold Heart Study
NCT04181255Phase 1Terminated
- Sponsor
- University of Michigan
- Start
- Feb 2020
- Primary completion
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Poractant alfa in hypoplastic left heart syndrome (HLHS) (2 arms), sponsored by University of Michigan. Primary endpoints: Number of days of mechanical ventilation, Number of days in the Pediatric Cardiothoracic Unit and 1 more. Started Feb 2020; status: terminated.
02
Drugs
Poractant alfa
03
Conditions
hypoplastic left heart syndrome (HLHS)
Beyond the preview
Go deeper on NCT04181255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04181255.